JP2022502062A - ２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法 - Google Patents

２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法 Download PDF

Info

Publication number
JP2022502062A
JP2022502062A JP2021517817A JP2021517817A JP2022502062A JP 2022502062 A JP2022502062 A JP 2022502062A JP 2021517817 A JP2021517817 A JP 2021517817A JP 2021517817 A JP2021517817 A JP 2021517817A JP 2022502062 A JP2022502062 A JP 2022502062A
Authority
JP
Japan
Prior art keywords
aon
fana
seq
cells
foxp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502062A5 (enExample
Inventor
ベーヌ アイシュワリヤー
ウェイン ダブリュー． ハンコック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Philadelphia
Original Assignee
Children's Hospital of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital of Philadelphia filed Critical Children's Hospital of Philadelphia
Publication of JP2022502062A publication Critical patent/JP2022502062A/ja
Publication of JP2022502062A5 publication Critical patent/JP2022502062A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021517817A 2018-09-26 2019-09-25 ２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法 Pending JP2022502062A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737061P 2018-09-26 2018-09-26
US62/737,061 2018-09-26
US201862739001P 2018-09-28 2018-09-28
US62/739,001 2018-09-28
PCT/US2019/053033 WO2020069044A1 (en) 2018-09-26 2019-09-25 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022502062A true JP2022502062A (ja) 2022-01-11
JP2022502062A5 JP2022502062A5 (enExample) 2022-10-04

Family

ID=69953290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517817A Pending JP2022502062A (ja) 2018-09-26 2019-09-25 ２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法

Country Status (7)

Country Link
US (1) US20210340536A1 (enExample)
EP (1) EP3856919A4 (enExample)
JP (1) JP2022502062A (enExample)
CN (1) CN112969799A (enExample)
AU (1) AU2019347849B2 (enExample)
CA (1) CA3112809A1 (enExample)
WO (1) WO2020069044A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3845646A1 (en) 2019-12-30 2021-07-07 Secarna Pharmaceuticals GmbH & Co. KG Modified antisense oligonucleotide for inhibition of foxp3 expression
WO2023235838A2 (en) * 2022-06-02 2023-12-07 Skyhawk Therapeutics, Inc. Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521556A (ja) * 2013-06-07 2016-07-25 ラナ セラピューティクス インコーポレイテッド Ｆｏｘｐ３発現を調節するための組成物及び方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346918T1 (de) * 1998-06-19 2006-12-15 Univ Mcgill Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
AU4031700A (en) * 1999-04-06 2000-11-02 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion
CA2419563C (en) * 2000-09-06 2018-03-20 Mcgill University Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
DK1470144T3 (da) * 2002-02-01 2009-04-06 Univ Mcgill Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
CA2652539A1 (en) * 2006-05-19 2007-11-29 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
WO2008066784A2 (en) * 2006-11-27 2008-06-05 Ludwig Institute For Cancer Research Expression of foxp3 by cancer cells
US20100310635A1 (en) * 2007-04-25 2010-12-09 Engin Ozkaynak Compositions and Methods for Regulating T-Cell Activity
EP2285961A4 (en) * 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION
WO2010048673A1 (en) * 2008-10-30 2010-05-06 Murdoch Childrens Research Institute Modulation of cellular differentiation and uses therefor
WO2010065671A2 (en) * 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2017181026A1 (en) * 2016-04-15 2017-10-19 Translate Bio Ma, Inc. Selective modulation of foxp3 expression
US20200030361A1 (en) * 2016-09-23 2020-01-30 City Of Hope Oligonucleotides containing 2'-deoxy-2'fluoro-beta-d-arabinose nucleic acid (2'-fana) for treatment and diagnosis of retroviral diseases
FR3058061A1 (fr) * 2016-10-27 2018-05-04 Selexel Nouvelle utilisation d'oligonucleotides double brin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521556A (ja) * 2013-06-07 2016-07-25 ラナ セラピューティクス インコーポレイテッド Ｆｏｘｐ３発現を調節するための組成物及び方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Why FANA?", INTERNET ARCHIVE WAYBACK MACHINE [ONLINE], JPN6023039179, 17 August 2018 (2018-08-17), ISSN: 0005308177 *
CANADIAN JOURNAL OF CHEMISTRY, vol. Volume 86, Number 7, JPN6023039180, 2008, pages 641 - 656, ISSN: 0005308176 *
CANCER RESEARCH, vol. Volume 78, Issue 13_Supplement, 5561, JPN6023039181, 1 July 2018 (2018-07-01), ISSN: 0005308175 *

Also Published As

Publication number Publication date
AU2019347849B2 (en) 2025-08-28
CA3112809A1 (en) 2020-04-02
EP3856919A4 (en) 2023-08-02
EP3856919A1 (en) 2021-08-04
WO2020069044A1 (en) 2020-04-02
CN112969799A (zh) 2021-06-15
AU2019347849A1 (en) 2021-05-20
US20210340536A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
JP7792249B2 (ja) 結合ドメイン
US12247982B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
US20230374503A1 (en) Combination
ES3042082T3 (en) Methods of making chimeric antigen receptor-expressing cells
CN106068276B (zh) 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
JP2021103174A (ja) バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法
JP2021102627A (ja) がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用
CA3097399A1 (en) T cell receptors with mage-b2 specificity and uses thereof
WO2018218231A1 (en) Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
JP2009514528A (ja) Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
JP2019529437A (ja) 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法
AU2019347849B2 (en) 2'FANA modified Foxp3 antisense oligonucleotides and methods of use thereof
JP2022500378A (ja) ユビキチン結合酵素ｅ２ｋ（ｕｂｅ２ｋ）を阻害することによる癌の治療法
CN114269920A (zh) 用于治疗癌症的方法和组合物
US20210000921A1 (en) Methods and compositions for modulating thymic function
KR20130102990A (ko) 항암면역우회암의 표시인자 및 무력화 표적으로서의 ａｐｉ５의 용도
CN109937051A (zh) 治疗tim-3升高的方法
JP2021523098A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
HK40050192A (en) 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof
US20230340127A1 (en) Methods and compositions for cancer treatment by inhibition of fbxo44
WO2025111533A1 (en) Car-t cells comprising a cdkn1b gene knockout and methods of use thereof
JP2022512745A (ja) がんを処置するためのｔｌｒ９調節因子
WO2023234297A1 (ja) がんを処置するための組成物
KR20260035590A (ko) Nk세포의 nkg2a 억제제 및 ilt2 억제제를 포함하는 면역항암치료의 효능 증진용 조성물 및 면역항암치료의 효능 증진 방법
JP2023128726A (ja) 癌を処置するためのｔｌｒ９モジュレーター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210520

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241114